Import Your Data

FAQ

More QuickView FAQs

QuickView

0
Meta-
Analysis

Bookmark Forward

QuickView for Cyclopentolate (compound)

Summary
General Info

PubChem

PubChem Compound 22162

PubChem Compound 22162

Name:	Cyclopentolate
PubChem Compound ID:	22162
Description:	A parasympatholytic anticholinergic used solely to obtain mydriasis or cycloplegia.
Molecular formula:	C₁₇H₂₆ClNO₃
Molecular weight:	327.846 g/mol
Synonyms:	EINECS 227-521-8; 5870-29-1; MLS000069583; Cyclopentolate hydrochloride [USAN:JAN]; D01002; SMR000058810; beta-Dimethylaminoethyl (1-hydroxycyclopentyl)phenylacetate hydrochloride; Cyclopentolate hydrochloride; Cyclopentolate hydrochloride (JP15/USP); 2-(2-(1-Hydroxycyclopentyl)-2-phenylacetoxy)ethyldimethylammonium chloride. show more » EINECS 227-521-8; 5870-29-1; MLS000069583; Cyclopentolate hydrochloride [USAN:JAN]; D01002; SMR000058810; beta-Dimethylaminoethyl (1-hydroxycyclopentyl)phenylacetate hydrochloride; Cyclopentolate hydrochloride; Cyclopentolate hydrochloride (JP15/USP); 2-(2-(1-Hydroxycyclopentyl)-2-phenylacetoxy)ethyldimethylammonium chloride; Cyclogyl (TN); Cyclogyl; 2-(Dimethylamino)ethyl 1-hydroxy-alpha-phenylcyclopentaneacetate hydrochloride; Cyclomydril; Cyclopentaneacetic acid, 1-hydroxy-alpha-phenyl-, 2-(dimethylamino)ethyl ester, hydrochloride; Benzeneacetic acid, alpha-(1-hydroxycyclopentyl)-, 2-(dimethylamino)ethyl ester, hydrochloride show less «

DrugBank

Identification

Name:	Cyclopentolate
Name (isomeric):	DB00979
Drug Type:	small molecule
Description:	A parasympatholytic anticholinergic used solely to obtain mydriasis or cycloplegia.
Synonyms:	Cyclopentolate HCL; Cyclopentolatum [INN-Latin]; Cyclopentylate; Cyclopentoiate; Diopentolate; Ciclopentolato [INN-Spanish]
Brand:	Pentolair, Ocu-Pentolate, Cylate, Cyclogyl, Mydrilate, Akpentolate, Minims Cyclopentolate, AK-Pentolate
Category:	Muscarinic Antagonists, Parasympatholytics, Antimuscarinic eye preparations, Mydriatics
CAS number:	512-15-2

Pharmacology

Indication:	Used mainly to produce mydriasis and cycloplegia for diagnostic purposes.
Pharmacology:	Cyclopentolate is an anti-muscarinic in the same class as atropine and scopolamine. Cyclopentolate blocks the receptors in the muscles of the eye (muscarinic receptors). These receptors are involved controlling the pupil size and the shape of the lens. Cyclopentolate thus induces relaxation of the sphincter of the iris and the ciliary muscles. When... show more » Cyclopentolate is an anti-muscarinic in the same class as atropine and scopolamine. Cyclopentolate blocks the receptors in the muscles of the eye (muscarinic receptors). These receptors are involved controlling the pupil size and the shape of the lens. Cyclopentolate thus induces relaxation of the sphincter of the iris and the ciliary muscles. When applied topically to the eyes, it causes a rapid, intense cycloplegic and mydriatic effect that is maximal in 15 to 60 minutes; recovery usually occurs within 24 hours. The cycloplegic and mydriatic effects are slower in onset and longer in duration in patients who have dark pigmented irises. show less «
Mechanism of Action:	By blocking muscarinic receptors, cyclopentolate produces dilatation of the pupil (mydriasis) and prevents the eye from accommodating for near vision (cycloplegia).
Absorption:	Absorbed following ophthalmic administration.
Toxicity:	Oral LD₅₀ in the rat is 4000 mg/kg and 960 mg/kg in the mouse. Symptoms of overdose include tachycardia, dizziness, dry mouth, behavioral disturbances, uncoordination and drowsiness.
Affected organisms:	Humans and other mammals

Interactions

Drug interaction:

Triprolidine	Triprolidine and Cyclopentolate, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects.
Trospium	Trospium and Cyclopentolate, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects.
Tacrine	The therapeutic effects of the central acetylcholinesterase inhibitor, Tacrine, and/or the anticholinergic, Cyclopentolate, may be reduced due to antagonism. The interaction may be beneficial when the anticholinergic action is a side effect. Monitor for decreased efficacy of both agents.

Targets

Muscarinic acetylcholine receptor M1